SAPARDIS S.A. (PUM) | WebDisclosure

Basculer en Français

8601	Companies
140631	Keywords
76564	Articles
75122	Press releases

Home
Companies
SAPARDIS S.A.

BRIEF

published on 03/11/2025 at 18:40, 26 days 20 hours ago

PUMA prévoit une croissance modérée en 2025 malgré les défis économiques

Rentabilité PUMA SE Croissance Des Ventes Prévisions Financières Perspectives 2025
PRESS RELEASE

published on 03/11/2025 at 18:35, 26 days 20 hours ago

EQS-Adhoc: PUMA SE: PUMA announces its Outlook for 2025
PUMA SE announces its Outlook for 2025, expecting sales growth amidst geopolitical tensions and economic challenges. Includes one-time costs and adjusted EBIT outlook

Sales Growth PUMA SE EBIT Outlook Outlook 2025 One-time Costs
BRIEF

published on 01/22/2025 at 18:27, 2 months 15 days ago

PUMA annonce une forte croissance de ses ventes et lance une initiative de profit

Optimisation Des Coûts Résultats Financiers 2024 Croissance De PUMA Programme De Niveau Supérieur Initiative De Rentabilité
BRIEF

published on 01/22/2025 at 18:27, 2 months 15 days ago

PUMA Reports Strong Sales Growth and Launches Profit Initiative

Cost Optimization Financial Results 2024 Nextlevel Program PUMA Growth Profitability Initiative
PRESS RELEASE

published on 01/22/2025 at 18:22, 2 months 15 days ago

PUMA accelerates growth throughout 2024 and initiates program to increase profitability
PUMA reports solid 2024 sales growth of 9.8% in Q4 and aims to enhance profitability. Launches 'nextlevel' program for cost optimization and efficiency improvement

Profitability Sales Growth Cost Optimization PUMA Nextlevel Program
BRIEF

published on 01/22/2025 at 18:21, 2 months 15 days ago

PUMA Reports Preliminary 2024 Financial Results

Sales Growth Operating Result PUMA 2024 Results Net Income Decline Cost Efficiency Program
BRIEF

published on 01/22/2025 at 18:21, 2 months 15 days ago

PUMA publie ses résultats financiers préliminaires pour 2024

Croissance Des Ventes Résultat D'exploitation Baisse Du Résultat Net Résultats PUMA 2024 Programme D'efficacité Des Coûts
PRESS RELEASE

published on 01/22/2025 at 18:16, 2 months 15 days ago

EQS-Adhoc: PUMA SE: PUMA announces preliminary results for the fourth quarter and the full year 2024
PUMA SE announces preliminary 2024 results: sales up by 9.8% in Q4, EBIT margin at 7.1%. Initiates 'nextlevel' program for 8.5% EBIT margin by 2027. Full results and outlook on 12 March 2025

Sales Growth Preliminary Results EBIT Margin PUMA SE Nextlevel Program
BRIEF

published on 11/06/2024 at 08:05, 5 months 1 day ago

PUMA annonce une croissance accélérée de ses ventes au troisième trimestre 2024

Perspectives Financières 2024 Résultats Financiers Du 3e Trimestre Croissance Des Ventes De PUMA Impact Des Devises Croissance De La Vente Directe Au Consommateur
BRIEF

published on 11/06/2024 at 08:05, 5 months 1 day ago

PUMA Reports Accelerated Sales Growth in Q3 2024

Direct-to-consumer Growth 2024 Financial Outlook Q3 Financial Results Currency Impact PUMA Sales Growth

Accesswire

Published on 04/07/2025 at 14:30, 27 minutes ago

Newsmax Enters into Standby Equity Purchase Agreement of Up to $1.2 Billion With Yorkville Advisors
Published on 04/07/2025 at 14:30, 27 minutes ago

Sparta Provides Update on Delay in Filing Annual Financial Statements
Published on 04/07/2025 at 14:00, 57 minutes ago

NOA Lithium Advances Towards 2025 Water Exploration at Rio Grande Project
Published on 04/07/2025 at 14:00, 57 minutes ago

Rio Grande Resources Announces the Successful Completion of Sampling and Field Campaign at the Winston Gold-Silver Project
Published on 04/07/2025 at 14:00, 57 minutes ago

Tharimmune Announces Positive Data with Novel Biparatopic PD-1/VEGF and Multispecific HER2/HER3 Biologics Leveraging Proprietary EpiClick(TM) Technology

View all ACCESSWIRE

EQS Group

Published on 04/07/2025 at 14:26, 31 minutes ago

Share Buyback
Published on 04/07/2025 at 14:24, 32 minutes ago

OTRS AG: Voluntary Public Tender Offer of Optimus BidCo AG
Published on 04/07/2025 at 13:00, 1 hour 57 minutes ago

CureVac Receives U.S. FDA IND Clearance to Initiate Phase 1 Clinical Trial for Novel mRNA-Based Precision Immunotherapy in Squamous Non-Small Cell Lung Cancer
Published on 04/07/2025 at 12:57, 2 hours ago

PFISTERER acquires long-standing partner Power CSL - portfolio expanded to include subsea solutions
Published on 04/07/2025 at 11:57, 2 hours 59 minutes ago

Share buyback: Announcement pursuant to Article 5 (1) (b) and (3) of Regulation (EU) No. 596/2014

Les Echos

Published on 04/07/2025 at 07:01, 7 hours 56 minutes ago

bioMérieux obtient le marquage CE pour LUMED™ APSS™, une solution logicielle de pointe pour aider à prendre des décisions en matière de bon usage des antibiotiques
Published on 04/07/2025 at 07:01, 7 hours 56 minutes ago

bioMérieux obtains CE-marking for LUMED™ APSS™, a cutting-edge software solution to aid medical decision-making in Antimicrobial Stewardship
Published on 04/04/2025 at 19:18, 2 days 19 hours ago

Mersen: Number of shares and voting rights as of March 31, 2025
Published on 04/04/2025 at 19:18, 2 days 19 hours ago

Mersen : nombre d'actions et de droits de vote au 31 mars 2025
Published on 04/04/2025 at 18:17, 2 days 20 hours ago

Reporting on share buyback transactions carried out between March 31 and April 3, 2025

View all LES ECHOS COMFI WIRE